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Summary
Objective—To quantify the structural characteristics and nanomechanical properties of aggrecan
produced by adult bone marrow stromal cells (BMSCs) in peptide hydrogel scaffolds and compare
to aggrecan from adult articular cartilage.
Design—Adult equine BMSCs were encapsulated in 3D-peptide hydrogels and cultured for 21 days
with TGF-β1 to induce chondrogenic differentiation. BMSC-aggrecan was extracted and compared
with aggrecan from age-matched adult equine articular cartilage. Single molecules of aggrecan were
visualized by atomic force microcopy-based imaging and aggrecan nanomechanical stiffness was
quantified by high resolution force microscopy. Population-averaged measures of aggrecan
hydrodynamic size, core protein structures and CS sulfation compositions were determined by size-
exclusion chromatography, Western analysis, and fluorescence-assisted carbohydrate
electrophoresis (FACE).
Results—BMSC-aggrecan was primarily full-length while cartilage-aggrecan had many fragments.
Single molecule measurements showed that core protein and GAG chains of BMSC-aggrecan were
markedly longer than those of cartilage-aggrecan. Comparing full-length aggrecan of both species,
BMSC-aggrecan had longer GAG chains, while the core protein trace lengths were similar. FACE
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analysis detected a ∼1:1 ratio of chondroitin-4-sulfate to chondroitin-6-sulfate in BMSC-GAG, a
phenotype consistent with aggrecan from skeletally-immature cartilage. The nanomechanical
stiffness of BMSC-aggrecan was demonstrably greater than that of cartilage-aggrecan at the same
total sGAG (fixed charge) density.
Conclusions—The higher proportion of full-length monomers, longer GAG chains and greater
stiffness of the BMSC-aggrecan makes it biomechanically superior to adult cartilage-aggrecan.
Aggrecan stiffness was not solely dependent on fixed charge density, but also on GAG molecular
ultrastructure. These results support the use of adult BMSCs for cell-based cartilage repair.
Keywords
Aggrecan; Bone-marrow stromal cell; Cartilage repair; Tissue engineering; Self-assembling peptide;
Molecular Nanomechanical properties
Introduction
Tissue engineering substitutes have great potential for the restoration of the biological function
of damaged and diseased cartilage,1 which has limited intrinsic self-regeneration capabilities.
Approaches to cartilage tissue engineering involve numerous design considerations involving
cell source (e.g. chondrocytes, synoviocytes, marrow/adipose-derived progenitor cells),
biocompatible scaffold chemistry and morphology, bioactive signaling factors that promote
cellular differentiation, maturation, and extracellular matrix synthesis, mechanical stimulation,
gene therapy, microenvironmental factors and bioreactors.2 While many tissue engineering
methodologies produce cartilage-like neo-tissues with similar macromolecular components
compared to the native cartilage extracellular matrix (ECM), a major challenge is to produce
constructs having biochemical, structural and biomechanical properties that are functionally
equivalent to cartilage in vivo.3
The overall composition and organization of neocartilage is typically characterized via
biochemical4,5, histological and immunohistochemical6 measures, while ECM molecular
constituents have been analyzed using various chromatographic7 and electrophoretic
techniques8,9. Tissue-level biomechanical measurements to quantify the compressive, tensile
and shear behavior10,11 of neocartilage are related to and ultimately determined by the
macromolecular constituents and assembly of the ECM12,13. Recently, high resolution imaging
and nanomechanical methodologies have been developed to directly visualize the detailed
intramolecular structure and probe the nanoscale mechanical properties of various ECM
constituents (e.g., aggrecan14,15, collagen16,17, hyaluronan18). These techniques provide an
understanding of molecule-to-molecule variability, intramolecular and local nanoscale
properties, and the ability to assess properties of selected sub-populations that cannot be
revealed by macroscopic measures which provide population averages. The combination of
new nanotechnological approaches with traditional biochemical, histological, and macroscopic
mechanical methods, can greatly assist in understanding, evaluating and optimizing a proposed
tissue engineered strategy.
Because aggrecan is the dominant compressive load-bearing macromolecule in cartilage
ECM19, its expression, synthesis, organization, and turnover are often used as biomarkers of
the chondrogenic potential of bone marrow stromal cells (BMSCs) in cell-based cartilage tissue
engineering20-22. Recent studies showed that the sulfated glycosaminoglycan (sGAG) content
of BMSC-seeded agarose and self-assembling peptide hydrogels was lower than that in parallel
hydrogels seeded with chondrocytes from skeletally-immature cartilage20,23, and varied with
scaffold material23,24. Aggrecan accumulated within BMSC-seeded constructs was
structurally different from that in native cartilage or in similar hydrogels seeded with
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chondrocytes. In agarose, BMSC-synthesized aggrecan was shown by Western analysis to be
primarily full-length22; in the peptide gel, atomic force microscopy (AFM) imaging showed
that BMSC-aggrecan had longer core protein and larger GAG chain length23. The
chondrogenic potential of adult human BMSCs was found to be independent of age or
osteoarthritis (OA)25, an advantage of using BMSCs over chondrocytes for autologous cell-
based cartilage repair26 for older OA patients, where the source and capacity of chondrocytes
are limited. Given these advantages of BMSC-based cartilage repair, rigorous molecular-level
characterization of BMSC-produced ECM is needed to further understand adult BMSC
chondrogenesis.
The goal of this study was to investigate aggrecan produced by adult equine BMSCs
encapsulated in peptide hydrogels and induced to undergo chondrogenic differentiation and to
compare with aggrecan extracted from age-matched adult equine articular cartilage. The
detailed molecular structure and properties of aggrecan were quantitatively assessed using high
resolution AFM-based approaches. First, the ultrastructure of these two aggrecan populations
was investigated via AFM-based single molecule imaging. Secondly, the aggrecan-GAG
sulfation patterns and extent of core protein proteolysis was characterized using fluorescence-
assisted carbohydrate electrophoresis (FACE)8, Western blot, and size-exclusion
chromatography analyses. Finally the nanomechanical properties of these two aggrecan
populations were evaluated using high resolution force microscopy. Adult BMSC-peptide
aggrecan demonstrated ultrastructural features and GAG sulfation similar to those of skeletally-
immature (young) cartilage aggrecan, and had increased compressive stiffness compared to
adult cartilage aggrecan.
Methods
Tissue Harvest
Cartilage tissue was harvested aseptically from the femoropatellar groove, and bone marrow
was harvested from three skeletally-mature (2-5 year-old adults) mixed-breed horses as
described previously23. Horses were euthanized at Colorado State University for reasons
unrelated to this study, and for conditions that would not affect either cartilage or bone marrow.
Marrow Stromal Cell Isolation
BMSCs were isolated and stored as previously described23. Marrow samples were washed in
PBS and fractionated by centrifugation to separate the nucleated cells from the red blood cells.
BMSCs were isolated by differential adhesion to tissue culture plastic. After BMSC colonies
reached local confluence, cells were detached and reseeded at 6×103 cells/cm2, expanded to
∼3×104 cells/cm2 over three days, and cryo-preserved. Before hydrogel encapsulation, BMSCs
were thawed and plated at 6×103 cells/cm2. After 3 days, cells were detached (passage-1) and
reseeded at 6×103 cells/cm2, and expanded for three days prior to encapsulation in peptide
hydrogels.
Hydrogel Encapsulation and Culture
KLD12 peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the MIT
Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide synthesizer
with FMOC protection. BMSCs were encapsulated in 0.35% (w/v) KLD12 peptide at a
concentration of 10×106 cells/ml using acellular agarose casting molds to initiate peptide
assembly as described previously23. BMSC-seeded disks (6.35mm-diam×1.6mm-thick) were
cultured in high glucose DMEM (Invitrogen, Carlsbad, CA) supplemented with 1% ITS+1
(final concentration: 10μg/ml insulin, 5.5μg/ml transferrin, 5ng/ml sodium selenite, 0.5mg/ml
bovine serum albumin, 4.7μg/ml linoleic acid, Sigma-Aldrich), 0.1μM dexamethasone (Sigma-
Aldrich, St. Louis, MO), 37.5μg/ml ascorbate-2-phosphate (Wako Chemicals, Richmond,
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VA), 1% PSA, 10mM HEPES, 400μM L-proline, 1mM sodium pyruvate, and 1% NEAA, with
10ng/ml rhTGF-β1 (R&D Systems, Minneapolis, MN) with medium changes every 2-3 days.
Disks were cultured for 21 days.
Aggrecan Extraction
Aggrecan was extracted from BMSC-peptide gels and native articular cartilage (Fig. 1a) with
4M guanidine HCl, 100mM sodium acetate, pH 6.8, containing Protease Complete inhibitor
mix (Roche, Indianapolis, IN) for 48 hours at 4°C with agitation27. Extracts were adjusted to
1.58g/ml by the addition of CsCl and centrifugation at 470,000 gav for 72 hours at 4°C. The
D1 fractions (>1.54g/ml) were desalted by dialysis against water, dried and used for AFM
imaging, nanomechanical testing, and Western analysis. Unfractionated GuHCl extracts were
also desalted and used for FACE analysis8.
AFM Imaging
D1 aggrecan samples at 50μg sGAG/ml in MilliQ water were deposited on 3-
aminopropyltriethoxysilane (APTES; Sigma Aldrich, St. Louis, MO) functionalized muscovite
mica substrates (SPI Supplies, West Chester, PA) and rinsed with MilliQ water after 30
minutes, as previously described14. Electrostatic interactions between the positively charged
APTES-mica and the negatively charged GAG chains retained aggrecan on the surface in a
relatively flat conformation14, despite rinsing in water. Tapping mode imaging (Fig.1b) was
performed in ambient conditions with a Nanoscope IIIa Multimode AFM (Veeco Instruments,
Plainview, NY) and Super Sharp Silicon AFM probes (nominal cantilever spring
constant=42N/m, nominal tip end radius <5 nm; Nanosensors, Switzerland). A thin layer
(0.2-1nm) of absorbed water is present on mica under ambient conditions28 which partially
hydrates the aggrecan.
Quantification of Aggrecan Single Molecule Dimensions
AFM height images were digitized into pixels and aggrecan structural features (ie. core protein
and GAG trace length) were traced and calculated automatically with a custom Matlab program
(The MathWorks, Natick, MA) or manually with SigmaScan Pro image analysis software
(SPSS Science, Chicago, IL). Full-length aggrecan were identified quantitatively by the
presence of G1 and G3 domains having increased height (>0.5nm) at the ends of the core
protein.
Aggrecan Nanomechanical Testing
Microcontact printing29 was employed to produce micrometer-sized hexagonally-patterned
surfaces of densely packed, chemically end-grafted aggrecan surrounded by a neutral hydroxyl-
terminated self-assembled monolayer (11-mercaptoundecanol, HS(CH2)11OH, OH-SAM)15
(Fig. 1c). A Multimode picoforce Nanoscope IV AFM (Veeco Instruments, Plainview, NY)
was used to perform compressive nanomechanical testing with an OH-functionalized spherical
colloidal probe tip15 (cantilever spring constant ∼0.12N/m, tip end radius ∼2.5μm; Novascan,
Ames, IA). Two measurements were employed to assess the mechanical stiffness of the
aggrecan. First, the absolute compressed height H of aggrecan as a function of applied normal
force was obtained by scanning parallel to the substrate surface and across the hexagon
region15 (Fig. 1d) using contact mode imaging over a wide range of normal forces (0∼30 nN),
and in aqueous solutions of 0.001 to 1M NaCl (pH∼5.6). Secondly, normal compression of
aggrecan was performed by having the probe tip approach perpendicularly to the substrate (z-
piezo displacement velocity =2μm/s, Fig. 1e). Raw data were converted to normal force as a
function of tip-to-substrate distance, D as described previously15. Do is defined as the D where
the force first increases above noise level. Normal stress was calculated from the normal force
using the surface element integration method15,30. The total sGAG content within a hexagon
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on the gold substrate was measured by dimethylmethylene blue dye assay (DMMB)4 after
testing. The initial sGAG density prior to compression, calculated by dividing the sGAG
content by pattern volume, was ∼20mg/ml (one aggrecan molecule per ∼25nm×25nm) at 0.1M
NaCl for both BMSC-peptide and cartilage-extracted aggrecan samples. sGAG density during
compression was calculated as a function of compressed height by normalizing the total sGAG
content under the probe tip to the reduced compressed volume. (This estimate of density
assumes minimal outward “bulging” of aggrecan at the radial periphery of the layer under the
tip. Since the tip diameter (2R)≫Do and, given the lateral constraint of the adjacent
uncompressed aggrecan, this assumption is reasonably well justified.)
Core Protein Heterogeneity
Aggrecan core protein heterogeneity was analyzed by Western blotting. Samples were treated
with protease-free chondroitinase ABC (30mU/100μg GAG), keratanase II (0.5mU/100μg
GAG) and endo-β-galactosidase (0.5mU/100μg GAG) (Seikagaku, Tokyo, Japan) and digests
corresponding to 10μg GAG were loaded on 4-15% polyacrylamide gels and probed with
antibodies to the aggrecan G1 (JSCATEG)31.
Relative Hydrodynamic Sizes of Aggrecan and GAG
Sephacryl S-1000 and Superose 6 FPLC chromatography (GE Healthcare, Piscataway, NJ)
were used to characterize the hydrodynamic size distributions of aggrecan monomers and their
constituent GAG chains, respectively. Aggrecan (200μg sGAG) was eluted on S-1000 at 30
ml/hr with 0.5M sodium acetate at pH 6.8. For GAG analysis, 100μg aggrecan was digested
with 50μg proteinase K in 200μl ammonium acetate (pH 7.2) for 48 hrs at 60 °C and 100μl of
the digest was eluted on Superose 6. Fractions (0.5 ml) were collected at 0.5ml/min and assayed
for sGAG by DMMB. The void volume Vo and total volume Vt were determined using 0.5μm
polystyrene beads and phenol red, respectively. The partition coefficient (Kav) was estimated
as (Ve -Vo)/(Vt -Vo), for each eluted fraction Ve.
FACE Analysis of GAG Sulfation
FACE analysis was performed on proteinase K digests of BMSC-peptide aggrecan from 3
different adult horses and cartilage-extracted aggrecan from 1 adult horse. Samples containing
2-10μg of sGAG were digested with chondroitinase ABC, disaccharide products fluorotagged
by reductive amination with 2-aminoacrodone, prior to separation and quantitation by
FACE8.
Statistical Analyses
Aggrecan and GAG molecular dimensions are reported as mean±SD in text and in figures for
population distribution. For data-sets having a unimodal distribution, a Gaussian fit was used
to test for normality, and the goodness of fit was evaluated by R2 (the summed mean squares
of the regression divided by the summed mean squares of the data). For normally distributed
data-sets, two-tailed, unpaired Student t-tests were performed to test for differences of the
means, with significance set at p<0.05. For non-unimodal distributions, a two-sample
Kolmogorov-Smirnov (K-S) test was performed to compare distributions of molecular
dimensions. For comparison between groups, 95% confidence intervals were used.
Results
Single molecule ultrastructure of BMSC-peptide and native cartilage aggrecan
AFM height images compare the ultrastructure of BMSC-peptide aggrecan (Fig. 2a-c) to
cartilage-extracted aggrecan (Fig. 2d-f). Individual aggrecan molecules were directly
visualized and the details of their intramolecular structure including the core protein and
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constituent GAG chains identified (Fig. 2b,c,e,f). In many cases, the brighter globular domains
(G1, G3) at the ends of the core protein (arrows in Fig. 2a,d) could be identified by their
increased height (>0.5 nm) relative to the rest of the molecule. Aggrecan with globular domains
at both N (G1)- and C (G3) termini were identified as “full-length,” i.e., those which had not
been enzymatically cleaved along the core protein32,33. The molecular dimensions of the
aggrecan from the two sources were strikingly different. The BMSC-peptide aggrecan had
noticeably longer GAG chains than cartilage-extracted aggrecan (Fig.2b,c vs. Fig. 2e,f,
quantified below). Moreover, short fragments (Fig. 2d, asterisks) were more pronounced in the
cartilage-extracted aggrecan population than in BMSC-peptide aggrecan (quantified below).
Core protein length distribution and heterogeneity
The distributions of the core protein trace length for the BMSC-peptide and cartilage-extracted
aggrecan were markedly different (K-S test, p<0.0001, Fig. 3a,b), with BMSC-peptide
aggrecan =440±138nm (mean±SD) and cartilage-extracted aggrecan =220±142nm. While the
length distributions were broad and nearly bimodal (Fig. 3a,b), the constituent sub-populations
of full-length aggrecan (Fig.2c,d) were both normally distributed with peaks at 487nm and
475nm that were not significantly different from each other (p=0.32). A large proportion
(∼40%) of the BMSC-peptide aggrecan was full-length (Fig. 3a,c), whereas the majority of
the cartilage aggrecan (∼86%) were fragments (Fig. 3b,d) consistent with proteolytic
degradation. Full-length cartilage-extracted aggrecan comprised a smaller sample size (n=20,
Fig. 3d) due to the lower proportion of full-length aggrecan observed in the whole population.
The difference in size of the molecular populations was also seen in the S-1000 chromatograms
(Fig. 3e): BMSC-peptide aggrecan eluted earlier (Kav =0.25) than the cartilage-extracted
aggrecan (Kav =0.42), consistent with the larger average hydrodynamic size of BMSC-peptide
aggrecan.
Western analyses were performed on the same samples to further assess the heterogeneity of
the core protein constituents by using antibodies against the G1 domain of the core proteins.
The BMSC-peptide aggrecan showed a greater abundance of high-molecular-weight species
reacting with anti-G1 antibody, consistent with a larger population of full-length aggrecan (Fig.
3f). The major G1-immunoreactive fragment seen in both the BMSC-peptide and cartilage-
extracted aggrecan samples was similar to the molecular weight of a previously characterized
calpain33-generated “double-globe” species (∼120kDa). In addition, the G1-containing bands
between 56-101kDa suggest that cartilage aggrecan may have undergone more extensive
proteolysis than the BMSC aggrecan. However, it may be difficult to assess the total extent of
proteolysis from this technique as such fragments could remain in lower density fractions and
be less well recovered.
GAG Chain Length and Sulfation
The distribution of individual GAG chain lengths within a single representative full-length
aggrecan in the BMSC and cartilage populations of Fig. 3c,d is shown in Fig. 4a,b, respectively.
The selected full-length BMSC-peptide aggrecan has longer average GAG length (47±8nm,
n=41 chains, Fig. 4a) than that of the single cartilage-aggrecan (17±7nm, n=44 chains, Fig.
4b). The GAG chains of this BMSC-peptide aggrecan also have a broader length distribution
than that of the cartilage-extracted aggrecan (Fig. 4a,b). For multiple aggrecan molecules, GAG
chain lengths were measured and an average chain length per molecule was calculated (Figs.
4c,d). The mean of the average GAG length per molecule was 44±10nm for BMSC-aggrecan
(n=299, Fig. 4c) and 20±4nm for cartilage-aggrecan (n=87, Fig. 4d). The n (number of
measured aggrecan molecules) in Fig. 4d was smaller than that in Fig. 3b because some
fragments did not have detectable GAG chains. For the full-length aggrecan populations of
Fig. 3c,d, the corresponding GAG trace length of BMSC-peptide aggrecan was about twice as
long as that of cartilage-aggrecan (Fig 4e,f). For both “all observed” (Fig. 4c,d) and “full-
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length” (Fig. 4e,f) aggrecan populations, the mean GAG chain length per aggrecan molecule
of the BMSC-peptide aggrecan was significantly longer than that of cartilage-extracted
aggrecan (p<0.0001). For each population (BMSC-peptide or cartilage-extract), the “all
observed” and “full-length” aggrecans had similar GAG lengths (p=0.175 and 0.642,
respectively).
The relative hydrodynamic size of BMSC- and cartilage-aggrecan GAG chains was also
assessed by Superose 6 size-exclusion chromatography (Fig. 3g). The BMSC-aggrecan GAGs
eluted at Kav =0.50 while cartilage-extracted GAGs eluted at Kav =0.71, corresponding to
average chain lengths of ∼60 disaccharides (27kDa, corresponding to ∼60nm contour length)
and ∼30 disaccharides (13kDa, ∼30nm), respectively35, assuming the proteinase K used here
and the papain digestion used previously35 generated single CS chains.
FACE analyses showed that aggrecan CS chains produced by peptide-encapsulated BMSCs
from 3 adult equines were composed of approximately equimolar amounts of 4- and 6-sulfated
disaccharides, a ratio characteristic of skeletally-immature and growing cartilage. In contrast,
the adult cartilage-extracted aggrecan showed a higher proportion of 6-sulfated disaccharides,
typical of adult cartilage36.
Aggrecan Compressive Stiffness
The three-dimensional AFM height images of microcontact printed substrates verified the
presence of clear hexagonal patterns of both BMSC-peptide and cartilage-extracted aggrecan
(Fig. 5a,b). Consistent with previous results15, the aggrecan height, H, decreased
monotonically with increasing ionic strength and with increasing normal force during a lateral
scan and reached the final incompressible height by ∼30nN force (Fig. 5c,d). The initial heights
at low force reflect the relative differences in lengths of the two aggrecan populations observed
via AFM imaging. At any given ionic strength, the BMSC-peptide aggrecan pattern showed
∼2-3 fold longer initial height than cartilage-aggrecan.
In the one-dimensional force-distance measurements (Fig. 5e,f), normal force increased
markedly with compression (decreasing D) as observed previously with fetal bovine
aggrecan15. At any given ionic strength, the BMSC-peptide aggrecan exerted a repulsive force
against tip at longer Do (e.g., Do ∼600nm for BMSC-peptide aggrecan and ∼200nm for
cartilage-aggrecan in 0.001M NaCl (Fig 5e,f)), reflecting the larger initial height and stronger
electrostatic repulsion interactions of BMSC-peptide aggrecan. The compressive properties
studied with these two different nanomechanical methodologies, height-force and force-
distance, coincide well with each other (Fig. 5g). The small difference between H and D at low
force (<5nN) was likely due to the tare force (∼100pN) necessary to enable stable feedback
during imaging15.
Finally, to directly compare the compressive stiffness of the two aggrecan populations
independent of their different initial heights (i.e., core protein lengths), the force-distance
curves of Fig. 5e,f were converted to stress versus DMMD-measured sGAG-concentration (see
Methods). At physiological ionic strength (0.1M NaCl), the normal stress increased markedly
with increasing compression (i.e., density of compressed GAG), but much more dramatically
for the BMSC-peptide aggrecan (Fig. 6).
Discussion
This study of aggrecan macromolecules from tissue-engineered constructs and native cartilage
involved the combination of high resolution AFM-based techniques to quantify nanoscale
structure and nanomechanical properties. Such an approach can provide a platform for
optimization of cell source, scaffold and culture conditions. AFM imaging enabled
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visualization of single molecules and their inter- and intramolecular heterogeneity. Marked
differences were observed between adult BMSC- and cartilage-aggrecan populations. BMSC-
aggrecan was predominantly full-length with fewer proteolytically degraded fragments and
much longer CS-GAG chains than cartilage aggrecan. These detailed AFM-based
measurements were consistent with size-exclusion chromatography and Western analyses. In
addition, AFM nanomechanical measurements showed that the compressive stiffness of the
BMSC-aggrecan was markedly higher than that of cartilage aggrecan. Taken together, these
results suggest that adult BMSC-aggrecan exhibits characteristics more similar to those of
skeletally-immature growth cartilage than to adult cartilage.
Imaging of single molecules revealed that aggrecan synthesized by adult BMSCs in peptide
hydrogel had an overall morphology qualitatively similar to that in adult cartilage, consisting
of a GAG-functionalized core protein19. However, the two aggrecan populations had strikingly
different molecular dimensions (Figs. 2,3). Based on AFM imaging, 50% of the BMSC-
aggrecan had a core protein length >400 nm, compared to only 16% of the cartilage-aggrecan
(Fig. 3a,b). S-1000 chromatography demonstrated average molecular sizes that were consistent
with AFM-based results. Western analyses suggested that the major G1-immunoreactive
constituents of cartilage-aggrecan were fragments which have been previously shown to be
generated by aggrecanases32 (G1-NITEGE) and m-calpain33 (G1-G2-GVA), though the action
of other proteinases cannot be excluded. In contrast, BMSC-peptide aggrecan was
predominantly full-length, typical of aggrecan from immature cartilage14,37. The activity of
aggrecan proteolytic enzymes is known to be regulated by TGF-β, but evidence exists for both
inhibition38 and upregulation39 of proteolysis. Interestingly, if compared to the aggrecan
produced by adult articular chondrocytes under the identical conditions with TGF-β
stimulation23, the adult BMSC-aggrecan have a larger proportion of full-length core proteins
than the adult chondrocyte-aggrecan. The full-length BMSC- and cartilage-aggrecan had
similar core protein trace lengths exhibiting a Gaussian distribution (Fig. 3c,d). Together, these
results suggest that the decreased average core protein trace length seen in the entire cartilage-
aggrecan population was due to proteolytic degradation.
The GAG chains of BMSC-aggrecan were found to be more than two times longer than that
of cartilage-aggrecan (Fig. 4). CS chain length has been shown to decrease with age in cartilage
tissue27,40 and is also smaller when synthesized by adult chondrocytes cultured in vitro,
reflecting an age dependent alteration of aggrecan-GAG synthesis41. Longer GAGs are
prevalent in aggrecan from immature cartilage40,42, growth plate35 and newly synthesized
aggrecan after injury43, as well as during the early stages of osteoarthritis44. The latter two
studies hypothesized that the increased CS chain length in injured and OA-cartilage were
indicative of growth cartilage metabolic phenotype. The CS sulfation fine structure analyses
are also consistent with such a conclusion. The sulfation patterns of CS-GAGs analyzed by
FACE have been studied previously as a characteristic of animal age, GAG chain termination,
tissue differentiation and development42,45,46. Adult BMSCs synthesized CS with ∼1:1
ΔDi6S-to-ΔDi4S ratio, similar to that observed previously in skeletally-immature and growing
cartilage35,36, while adult cartilage contained aggrecan predominantly with 6S-sulfated CS
(Fig. 4h), consistent with previous studies36. The differences in the GAG structure between
the two aggrecan populations in this study suggest that adult BMSCs undergoing
chondrogenesis in peptide hydrogels exhibit a very different pattern of glycosylation than adult
chondrocytes in native tissue.
The exact mechanisms whereby cells control CS chain length and sulfation pattern are still
under study. TGF-β has been shown to affect CS-GAG synthesis; for example, TGF-β-
stimulated fibroblasts produced elongated CS-GAG chains. In our recent study23 in which
animal-matched articular chondrocytes and BMSCs from immature or adult equines were
cultured under identical conditions for 3 weeks in the same peptide hydrogel and in the same
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(TGF-β1-containing) medium, the BMSCs produced longer GAG chains than the animal-
matched chondrocytes. This observation suggests that longer GAG chains are not just a result
of TGF-β stimulation, but also a reflection of cell type. Since the GAGs contribute to the
stiffness of cartilage, and proteolytic loss of protein-bound GAGs is a major characteristic of
osteoarthritis, the BMSC-aggrecan would appear to have a more favorable GAG structure for
cartilage mechanical function than the adult cartilage-aggrecan.
A major finding in the present study was the demonstration that BMSC-aggrecan was
demonstrably stiffer in nanomechanical compression than cartilage-aggrecan. The BMSC-
aggrecan population had a larger average core protein length; thus, its pattern height (Fig. 5c,d)
and tip-substrate separation distance were larger than that of cartilage-aggrecan at the same
normal force and ionic strength (Fig. 5e,h). In order to compare their intrinsic stiffness
independent of aggrecan dimensions, the force-distance curves were converted to curves of
stress versus DMMB-measured sGAG concentration (Fig. 6). Upon compression by the AFM
tip, which increased sGAG concentration under the tip, the BMSC-aggrecan exhibited larger
compressive stress. The macroscopic compressive moduli of bulk cartilage are known to
correlate well with the concentration of specific ECM constituents12,47 such as collagen and
GAG; and the correlation with GAG is ascribed to sGAG fixed charge density47. However,
our observation indicates that at the nanoscale, not only the constituent sGAG charge density,
but the molecular structure and dimensions of the GAGs can affect compressive stiffness. The
longer CS chains of BMSC-aggrecan may result in more intermolecular entanglement, steric
and stronger excluded volume effects during deformation. In addition, electrostatic interactions
between highly charged, closely-spaced rod-like chains are known to cause higher and more
nonlinear increases in repulsive stress compared to that caused by compression of spatially
homogeneous densities of fixed charge15,48. These phenomena may be particularly important
in localized regions such as the microenvironment of cells, e.g. the pericellular matrix, which
can be stimulated by mechanical forces. It also suggested that the stiffer BMSC-produced
constructs in comparison with the chondrocyte-produced constructs we reported
previously23 may not only due to the more total matrix content of the BMSC construct, but
also due to the longer GAG chain and core protein length of BMSC-aggrecan. The greater
stiffness of BMSC-aggrecan is also an attribute of immature native aggrecan49 and may be
advantageous to cartilage repair.
Taken together, the nanomechanical properties of adult BMSC-peptide aggrecan appear
superior to that of adult native cartilage aggrecan. Adult BMSCs are thus a promising cell
candidate for cell-based tissue engineering for cartilage repair and regeneration. Of course,
additional challenges must be met to achieve successful cartilage repair in vivo, including the
assembly of an appropriate collagen architecture and the synthesis and assembly of other matrix
macromolecules to enable integration with the surrounding tissues. The combined
methodologies utilized here can be applied to optimize the cell source and culture for
engineering desired ECM assemblies. The detailed structure and nanomechanical properties
of aggrecan and other ECM molecules can provide insights into the molecular determinants to
the integrity and functionality of cartilage repair.
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Fig 1.
(a). Aggrecan was extracted from adult equine BMSC-peptide gels (after 21 days of culture)
and from adult equine articular cartilage. The model of full-length aggrecan shows the globular
domain structures labelled as G1,G2,G3, linked by a core protein substituted with keratan
sulfate (KS) and, chondroitin sulfate (CS). (b) An illustration of aggrecan imaging using AFM
tapping mode. Aggrecan molecules were immobilized on the APTES-modified mica substrate
in a flattened conformation and imaged by a sharp silicon probe tip. (c) Illustrations of AFM
nanomechanical testing. Micro-contact-printed aggrecan patterns were surrounded by self-
assembled monolayer molecules (11-mercaptoundecanol, HS(CH2)11OH, OH-SAM). A
spherical gold-coated glass tip (functionalized with of OH-SAM) was used to scan and
compress the aggrecan patterns. The experiment was performed in 0.001-1.0M NaCl (pH ∼
5.6). (d) Height-normal force measurement: contact mode imaging was used to apply a range
of normal compressive forces while scanning across the patterned surface to measure the
compressed height H of aggrecan. (e) Normal force-distance measurements: direct
compression of aggrecan was performed by having the probe tip approach the surface
perpendicular to the plane of the substrate and measuring the force as a function of tip-to-
substrate distance D.
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Fig. 2.
AFM height images of aggrecan monomers. (a)-(c) Aggrecan produced by adult equine
BMSCs seeded in peptide hydrogel. (d)-(f) Aggrecan extracted from adult equine articular
cartilage. In (a) and (d), the globular domains of full length aggrecan are indicated by arrows.
Example of short degraded aggrecan fragments (∼100 nm) are marked by asterisks in (d).
Examples of core protein and GAG chain traces are shown in (b).
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Fig. 3.
Core protein analyses. Core protein trace length distributions of (a) BMSC-peptide aggrecan
and (b) cartilage-extracted aggrecan measured from the AFM height images. (Mean ± SD is
noted in each histogram. n = number of measured aggrecan molecules.) The distributions of
the two core protein populations (a,b) are markedly different (K-S test, p<0.0001). Core protein
trace length distributions of full-length (c) BMSC-peptide aggrecan and (d) cartilage-extracted
aggrecan. Gaussian curves were fit to both distributions; the goodness of fit R2 is 0.997 and
0.974 in (c) and (d), respectively. These two core protein length distributions (c,d) are not
significantly different (two-tailed t test, p = 0.3531.) (e) Elution profiles of BMSC-peptide and
cartilage-extracted aggrecan on a Sephacryl S-1000 column. Kav = 0.25 for the BMSC-peptide
aggrecan and 0.42 for the cartilage-extracted aggrecan, indicating the greater hydrodynamic
size of BMSC-peptide aggrecan. (f) Western blot analysis with anti-G1 antibody. High
molecular weight core protein as well as low molecular weight core fragment species (*) were
detected in both BMSC-peptide and cartilage-extracted aggrecan samples.
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Figure 4.
GAG chain length and composition analysis. Distribution of GAG trace lengths on one selected
single representative (a) BMSC-peptide aggrecan and (b) cartilage-extracted full-length
aggrecan. Mean ± SD is noted in each histogram. n = number of measured GAG chains.
Distribution of average GAG chain lengths for multiple (c) BMSC-peptide aggrecan and (d)
cartilage-extracted aggrecan. n = number of measured aggrecan molecules. Distribution of
average GAG chain length on multiple full-length (e) BMSC-peptide aggrecan and (f)
cartilage-extracted aggrecan. n = number of measured aggrecan molecules. The goodness of
the Gaussian fit R2 in (c)-(f) is 0.971, 0.968, 0.901 and 0.999, respectively. (g) Superose 6
chromatography shows the BMSC-peptide GAG population is longer than the cartilage-
extracted GAG population with Kav =0.50 and 0.71, respectively. (h) FACE analysis of
aggrecan produced by BMSCs derived from 3 adult horses and that of aggrecan extracted from
adult cartilage. The BMSC-peptide aggrecan showed an approximately equal amount of ΔDi6S
and ΔDi4S in contract to the increased ΔDi6S content of cartilage-extracted aggrecan.
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Fig. 5.
Nanomechanical testing. (a,b) AFM three-dimensional height images of (a) BMSC-peptide
and (b) cartilage-extracted aggrecan chemically end-grafted on gold substrates and patterned
by micro-contact printing. The images were taken in 0.001M NaCl with a minimal applied
normal force ∼100 pN. (c,d) Compressed aggrecan height H versus normal force curves of (c)
BMSC-peptide and (d) cartilage-extracted aggrecan in different ionic strength aqueous solution
were measured by contact mode AFM. Insert in (d) shows the direction of the scan and the
corresponding compressed height H. Each data point represents the average aggrecan height
from 8 scans across the pattern at a given normal force and NaCl concentration. The standard
deviation (SD) of each data point is smaller than the size of the data point. (e,f) Normal force
versus distance curves of (e) BMSC-peptide and (f) cartilage-extracted aggrecan during normal
compression as shown in the insert in (f). The probe tip approaches the substrate perpendicular
to the plane of the substrate. Each curve is an average of 30 approaches in different locations
on the pattern. The SD of each averaged curve is smaller than the line width. (g) Comparison
of the height-normal force measurement (open triangles, replotted from Fig. 5c,d, 0.01M NaCl)
and normal force-distance measurements (lines, replotted from Fig. 5e,f, 0.01M NaCl). Data
measured using two different methods well coincide. Some slight discrepancy at low normal
force (< 5 nN) is possibly due to the finite normal force necessary for maintaining stable
feedback during the contact mode scanning.
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Fig. 6.
Stress-sGAG concentration curves converted from the force-distance curves in Fig 5 e,f (0.1M
NaCl). The initial uncompressed sGAG concentration was the total sGAG amount measured
by DMMB divided by the aggrecan pattern volume measured by AFM height images. Normal
stress was calculated from the force using the surface element integration method30. Upon
compression by the probe tip, the sGAG density of the end-grafted aggrecan under the probe
tip increased due to the decrease in compressed volume. When both aggrecan patterns were
compressed to the same sGAG concentration, BMSC-peptide aggrecan exhibited greater stress
than the cartilage-extracted aggrecan. (note: GAG concentration in native tissue is 20-80 mg/
ml)47. Each curve is an average of 30 approaches in different locations on the aggrecan pattern.
The 95% confidence intervals of each averaged curve are smaller than the line width.
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